Biohazard2020/2021-COVID-19 novel coronavirus (2019-nCoV))病毒: 新型冠状病毒 2019-nCoV

Moorestown, New Jersey, United States

7322321334

7322321334

  • biotecMAX
    • BioHazard2020-3
    • BioHazard2020-2
    • BioHazard2020-1
    • BioHazard2020-0
    • 2021-1
    • 2020-6
    • 2020-5
    • 2020-4
    • 2020-3
    • 2020-2
    • 2020-1
    • 2019-12
    • 2019-11
    • 2019-10
    • 2019-9
    • 2019-8
    • 2019-7
    • 2019-4
    • 2019-3
    • biotecNOVA 2
    • BiotecNOVA 1
    • biotecHOPE
    • biotecHEART
    • portfolio
    • BiotecDATA
    • biotechVORTEX 2
    • biotechVORTEX 1
    • biotechSTORM/BiotecWARS
    • blogs
    • about
    • biotecMAX
    • BioHazard2021
      • BioHazard2020-3
      • BioHazard2020-2
      • BioHazard2020-1
      • BioHazard2020-0
    • BiotecMAX2021
      • 2021-1
    • biotecMAX2020
      • 2020-6
      • 2020-5
      • 2020-4
      • 2020-3
      • 2020-2
      • 2020-1
    • BiotecMAX2019
      • 2019-12
      • 2019-11
      • 2019-10
      • 2019-9
      • 2019-8
      • 2019-7
      • 2019-4
      • 2019-3
    • biotecNOVA
      • biotecNOVA 2
      • BiotecNOVA 1
    • BiotecHOPE
      • biotecHOPE
      • biotecHEART
    • biotecAlpha
      • portfolio
      • BiotecDATA
    • BiotechVortex
      • biotechVORTEX 2
      • biotechVORTEX 1
    • BiotecWARS
      • biotechSTORM/BiotecWARS
    • seeking biotech alpha
      • blogs
      • about
  • biotecMAX
seeking biotech alpha

seeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotech

seeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotechseeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotech

BiotechVortex™

image792

Vortexes are powerful and transformational centers of energy

 The BiotechVortex™ section of this site was created when I started seeing an increase in partnerships, mergers, and co-operative agreements, in both the biotech and medtech sectors. Here we will highlight these partnerships/agreements/mergers, even when no  specific products are identified.  

image793

BiotechVORTEX - First Group Page

image794

BiotechVortex™ - Second Group Page

BiotechVortex™

Gilead and Vir Biotechnology Establish Clinical Collaboration

Lilly and Merus NV Announce Collaboration

image795

Lilly and Merus NV Announce Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

Lilly and Merus NV Announce Collaboration

image796

 

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

January 19, 2021 Download PDF

INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.


 For additional information, please visit Merus' website, www.merus.nl and https://twitter.com/MerusNV. 


 To learn more about Lilly, please visit us at www.lilly.com. 

https://www.lilly.com/


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies-301210513.html 

 

Our Pipeline

The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.

https://merus.nl/pipeline/


https://seekingalpha.com/symbol/LLY


Our Pipeline The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.

Gilead and Vir Biotechnology Establish Clinical Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

Gilead and Vir Biotechnology Establish Clinical Collaboration

image797

 

January 12, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

-- First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research --

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).  

 

Gilead and Vir Biotechnology Establish Clinical Collaboration  

The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy® (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.


 VEMLIDY  

INDICATION

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please click here to see full Prescribing Information for VEMLIDY, including BOXED WARNING.

https://www.vemlidy.com/


 Please see Important Facts about VEMLIDY, including important warnings. 


 For more information, please visit www.vir.bio. 


  For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 

 

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

Tue January 12, 2021 8:00 AM|GlobeNewswire|About: GILD, VIR

– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –

FOSTER CITY, Calif. and SAN FRANCISCO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Vir Biotechnology, Inc. (VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).

https://seekingalpha.com/pr/18147900-gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination 

 

Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting

Jan. 12, 2021 8:12 AM ET Gilead Sciences, Inc. (GILD) By: Aakash Babu, SA News Editor1 Comment

  • Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) announces that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).

https://seekingalpha.com/news/3650652-gilead-and-vir-biotechnology-tie-up-in-chronic-hepatitis-b-virus-cure-setting


https://seekingalpha.com/symbol/GILD


https://seekingalpha.com/symbol/VIR


WHAT IS VEMLIDY? VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease. VEMLIDY may lower the amount of HBV in your body. VEMLIDY may improve the condition of your liver.

tislelizumab

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Gilead and Vir Biotechnology Establish Clinical Collaboration

image798

 

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Back to News Archive

Jan 11, 2021

  • Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
  • Novartis secures development and commercialization rights in North America, Europe, and Japan
  • Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
  • Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors


Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.


 

tislelizumab

 Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for certain patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma. In addition, BeiGene has filed three supplemental new drug applications for tislelizumab in China for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable HCC. 


 Find out more at https://www.novartis.com. 


 

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

Mon January 11, 2021 4:30 PM|Business Wire|About: BGNE

Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries

BeiGene (BGNE) to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales

BeiGene has the option to co-detail tislelizumab in North America

Both parties have freedom to conduct combination trials globally

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- BeiGene, Ltd.

https://seekingalpha.com/pr/18147035-beigene-announces-collaboration-novartis-to-develop-and-commercialize-anti-pdminus-1-antibody


https://seekingalpha.com/symbol/BGNE


https://seekingalpha.com/symbol/NVS


 

BeiGene, Novartis in Pact to develop tislelizumab for cancer settings

Jan. 11, 2021 4:47 PM ET BeiGene, Ltd. (BGNE)

By: Vandana Singh, SA News Editor

  • BeiGene (NASDAQ:BGNE) has announced a collaboration and license agreement with Novartis Pharma (NYSE:NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab. https://seekingalpha.com/news/3650509-beigene-novartis-in-pact-to-develop-tislelizumab-for-cancer-settings

https://www.beigene.com/science-and-product-portfolio/pipeline/tislelizumab



Tislelizumab

Biogen, Genentech team up for a new neurodegenerative biotech

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

image799

 

Biogen, Genentech team up for a new neurodegenerative biotech

Jan. 11, 2021 12:40 PM ET Roche Holding AG (RHHBY) By: Vandana Singh, SA News Editor

  • Atalanta Therapeutics launches today with a Series A financing exclusively by F-Prime Capital.

 

Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases

Mon January 11, 2021 6:00 AM|Business Wire|About: BIIB, JNP

- Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases -

- Founders are world-leading experts in RNA interference, including Nobel (NLCI) laureate Craig Mello -

- Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor -

BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics,

https://seekingalpha.com/pr/18145379-atalanta-therapeutics-launches-110-million-to-pioneer-rnai-therapeutics-for-neurodegenerative


 Preclinical research published in Nature Biotechnology has shown that branched siRNA can achieve unparalleled distribution in the CNS, including deep brain structures, and prolonged duration of effect. 


 For more information, visit www.atalantatx.com  


 F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com  

https://fprimecapital.com/


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005327/en/ 

 

Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling

by Nick Paul Taylor | Jan 11, 2021 9:15am 

https://www.fiercebiotech.com/biotech/biogen-genentech-and-f-prime-power-new-neurodegenerative-biotech-to-110m-unveiling


https://seekingalpha.com/symbol/BIIB


https://seekingalpha.com/symbol/RHHBY


https://www.atalantatx.com/

Our science & focus Our proprietary branched siRNA construct opens new frontiers in treating neurodegenerative diseases

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

image800

 

BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL BIOMARKERS OF COGNITIVE HEALTH USING APPLE WATCH AND IPHONE

January 11, 2021 at 7:30 AM EST

  • The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease 
  • Cognitive health — the ability to think clearly, to learn and to remember — is an indicator of brain health and important to performing daily activities  

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). 


  information that may be important to investors on our website at www.biogen.com. 



 “Working in collaboration with Biogen, we hope this study can help the medical community better understand a person's cognitive performance by simply having them engage with their Apple Watch and iPhone,” said Jeff Williams, Apple’s chief operating officer. “We’re looking forward to learning about the impact our technology can have in delivering better health outcomes through improved detection of declining cognitive health.” 


https://www.biogen.com/en_us/home.html


 

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

Mon January 11, 2021 7:30 AM|GlobeNewswire|About: BIIB 

https://seekingalpha.com/pr/18145641-biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-using

 

Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health

Jan. 11, 2021 8:33 AM ET Biogen Inc. (BIIB) By: Vandana Singh, SA News Editor3 Comments

  • Biogen (NASDAQ:BIIB) 

https://seekingalpha.com/news/3650238-biogen-apple-collaborate-to-evaluate-device-role-in-digital-biomarkers-of-cognitive-health


https://www.biogen.com/en_us/pipeline.html


https://seekingalpha.com/symbol/BIIB



Pipeline

Chi-Med and Inmagene Announce Strategic Partnership

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Sanofi to acquire Kymab, adding KY1005 to its pipeline

image801

  11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug (“IND”) submission. If successful, Inmagene will then move the drug candidates through global clinical development.


 For additional information about Inmagene Biopharmaceuticals, please visit www.inmagenebio.com. 


 

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Sun January 10, 2021 8:00 PM|GlobeNewswire|About: HCM

HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”)

https://seekingalpha.com/pr/18145186-chi-med-and-inmagene-announce-strategic-partnership-to-develop-and-commercialize-portfolio-of


 

Chi-Med and Inmagene ink deal to develop candidates in immunological diseases

Jan. 11, 2021 12:54 AM ET Hutchison China MediTech Limited (HCM) By: Mamta Mayani, SA News Editor

  • Hutchison China MediTech (NASDAQ:HCM)

https://seekingalpha.com/news/3650130-chi-med-and-inmagene-ink-deal-to-develop-candidates-in-immunological-diseases


https://www.chi-med.com/

https://seekingalpha.com/symbol/HCM

PRODUCTS AND TECHNOLOGY

Sanofi to acquire Kymab, adding KY1005 to its pipeline

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Sanofi to acquire Kymab, adding KY1005 to its pipeline

image802

 January 11 2021

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

 

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

*Continues to build on Sanofi’s leading presence in immunology aligned with strategy to pursue best-in-class treatments in defined areas

PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.


 For more information on Kymab please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited. 


 

KY1005: Promising antibody for inflammatory disorders

In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures.

“This acquisition aligns with our strategy of targeting fundamentally important disease pathways.  We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Ph.D., Global Head of Research & Development at Sanofi.

Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities.


 

Sanofi to buy Kymab for $1.45B

Jan. 11, 2021 3:30 AM ETSanofi (SNY)By: Mamta Mayani, SA News Editor

  • Sanofi (NASDAQ:SNY) to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.

https://seekingalpha.com/news/3650134-sanofi-to-buy-kymab-for-1_45b


https://seekingalpha.com/pr/18145263-sanofi-to-acquire-kymab-adding-ky1005-to-pipeline-human-monoclonal-antibody-targeting-key


https://www.sanofi.com/en

https://seekingalpha.com/symbol/SNY




Pipeline : We are utilizing our technology platforms to develop product candidates for immune disorders, cancer and haematological diseases.

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

image803

 

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

With support from the Centers for Disease Control and Prevention (CDC), Illumina and Helix have already identified more than 50 cases of the new variant in the US

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.


 To learn more, visit www.illumina.com 

https://www.illumina.com/

https://seekingalpha.com/symbol/ILMN



 Learn more at www.helix.com. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006007/en/ 


https://seekingalpha.com/pr/18140628-illumina-and-helix-collaborate-to-assess-prevalence-of-new-sars-covminus-2-uk-variant-b-1_1-7


 

Illumina gets CDC backing to track emergence of new COVID-19 strains

Jan. 09, 2021 1:55 PM ETIllumina, Inc. (ILMN)By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3650113-illumina-gets-cdc-backing-to-track-emergence-of-new-covidminus-19-strains


https://www.helix.com/


Large-scale COVID-19 testing & screening Helix is expanding access to high-sensitivity molecular COVID-19 testing with next-day** turnaround time for health systems, employers, governments, and other organizations across the country.

Blacksmith Medicines launches with seed funding and a research collaboration with Lilly

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US

image804

 

Blacksmith Medicines launches with seed funding and a research collaboration with Lilly

-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines –

– Research collaboration combines Blacksmith’s innovative chemistry platform with Lilly’s research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M –

SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics, a leading antibiotic discovery company discovering therapies to combat the rise of drug resistance.


 For further information, please visit the company’s website at www.BlacksmithMedicines.com  


 Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes. 

https://blacksmithmedicines.com/technology/


https://blacksmithmedicines.com/

 

Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M

Jan. 08, 2021 8:43 AM ET Eli Lilly and Company (LLY) By: Dulan Lokuwithana, SA News Editor1 Comment 

https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m  

 

Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly

-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines -

- Research collaboration combines Blacksmith's innovative chemistry platform with Lilly's research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M -

https://www.prnewswire.com/news-releases/blacksmith-medicines-launches-with-seed-funding-and-a-research-collaboration-with-lilly-301203230.html?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link


https://www.lilly.com/

https://seekingalpha.com/symbol/LLY



Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes.

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

image805

 

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

 Los Angeles, CA, USA, January 7, 2021 – ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. 


 For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com. 


 

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Thu January 7, 2021 3:00 AM|PR Newswire|About: PFE

LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

https://seekingalpha.com/pr/18142445-imaginab-announces-license-and-supply-agreement-pfizer-for-cd8-immunopet-technology


 

View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology-301202156.html


https://www.pfizer.com/

https://seekingalpha.com/symbol/PFE


 

ImaginAb inks supply deal with Pfizer for CD8 ImmunoPET technology in Cancer

Jan. 07, 2021 3:29 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor 

https://seekingalpha.com/news/3649479-imaginab-inks-supply-deal-pfizer-for-cd8-immunopet-technology-in-cancer



Optimizing combination therapies Visualizing immune response to inform the best immunotherapy treatment combinations.

PerkinElmer to Acquire Oxford Immunotec Global PLC

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

image806

Home / Investors / News releases News release details PerkinElmer to Acquire Oxford Immunotec Global PLC

PerkinElmer to Acquire Oxford Immunotec Global PLC

 January 7, 2021 at 7:00 AM ESTPDF Version

  • PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash
  • Transaction expected to be completed in the first half of 2021

WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”).


 Additional information can be found at www.OxfordImmunotec.com. 

 

Product Pipeline

Our Focus

Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.

http://www.oxfordimmunotec.com/north-america/science/product-pipeline/


http://www.oxfordimmunotec.com/north-america/

 

PKI

PerkinElmer to acquire Oxford Immunotec for $591M
Today, 7:14 AM


https://www.perkinelmer.com/

https://seekingalpha.com/symbol/PKI


Product Pipeline Our Focus Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.

BiotechVortex™

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

image807

 

January 06, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005129/en/


 For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com. 


 For more information on Kite, please visit www.kitepharma.com. 


 For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 


 

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

Wed January 6, 2021 8:00 AM| Business Wire| About: GILD

SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT)

https://seekingalpha.com/pr/18141148-kite-and-oxford-biotherapeutics-establish-cell-therapy-research-collaboration-in-blood


https://seekingalpha.com/symbol/GILD

 

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Jan. 06, 2021 2:24 PM ET Gilead Sciences, Inc. (GILD)By: Vandana Singh, SA News Editor2 Comments

  • Kite, a Gilead Company (GILD +3.1%) and Oxford BioTherapeutics have entered into a research collaboration to evaluate five targets for a number of hematologic and solid tumor indications, using latter's OGAP target discovery platform.

https://seekingalpha.com/news/3649376-gileads-kite-oxford-biotherapeutics-ink-immuno-oncology-pact



OBT IO PIPELINE

Biogen inks deal for ophthalmic gene therapy development

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

image808

 

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Tue January 5, 2021 2:00 AM|GlobeNewswire|About: BIIB

  • Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
  • The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections


MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (BIIB) (Nasdaq: BIIB, Cambridge, Mass., USA)


 For further information, please visit www.vigeneron.com. 


https://www.biogen.com/

https://seekingalpha.com/symbol/BIIB

 

Pipeline

https://www.biogen.com/en_us/pipeline.html


 

Biogen inks deal for ophthalmic gene therapy development

Jan. 05, 2021 2:39 AM ET Biogen Inc. (BIIB)

By: Mamta Mayani, SA News Editor4 Comments 

https://seekingalpha.com/news/3648630-biogen-inks-deal-for-ophthalmic-gene-therapy-development


Pipeline ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two lead programs in development for inherited retinal diseases where no approved treatment options are currently available.

Zai Lab and Cullinan Oncology Announce Strategic Collaboration

Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

image809

 

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

Mon December 28, 2020 7:30 AM|GlobeNewswire|About: ZLAB

- Zai Lab (ZLAB) to lead development and commercialization of CLN-081 in Greater China

- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties

- Zai Lab to join ongoing global trial for CLN-081

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited, an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology  

 

About CLN-081

CLN-081 is an orally available, small-molecule, next-generation, irreversible EGFR inhibitor designed to selectively target cells expressing mutant EGFR variants. CLN-081 is currently in a Phase 1/2a dose escalation and expansion trial evaluating oral, twice-daily administration of various doses in patients with NSCLC harboring EGFR Ex20ins mutations who have had at least one prior treatment with platinum-based chemotherapy or another approved standard therapy. 


 For additional information about the company, please visit www.zailaboratory.com  


 For additional information, please visit www.cullinanoncology.com. 

https://seekingalpha.com/symbol/CGEM


https://www.cullinanoncology.com/


http://www.zailaboratory.com/

https://seekingalpha.com/symbol/ZLAB

 

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

December 28, 2020 at 7:30 AM ESTPDF Version

- Zai Lab to lead development and commercialization of CLN-081 in Greater China

- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties

- Zai Lab to join ongoing global trial for CLN-081

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.

https://zailab.gcs-web.com/news-releases/news-release-details/zai-lab-and-cullinan-oncology-announce-strategic-collaboration


https://seekingalpha.com/news/3647483-zai-lab-and-cullinan-oncology-ink-strategic-collaboration-and-license-agreement

We are advancing a portfolio of cancer therapies in various stages of preclinical and clinical development. Each candidate is structured as a separate company, a wholly owned subsidiary, with development managed centrally by the Cullinan Oncology team.

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck

image810

 

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers

Wed December 23, 2020 10:07 AM|PR NewswirePR Newswire

AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com)


https://www.a2bio.com/our-science


 

For more information, visit www.a2bio.com. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/a2-biotherapeutics-enters-into-collaboration-agreement-with-merck-to-develop-allogeneic-cell-therapy-for-solid-tumor-cancers-301197998.html

SOURCE A2 Biotherapeutics


https://seekingalpha.com/symbol/MRK


 

Merck, A2 Bio in development pact for allogeneic cell therapy candidates for cancer

Dec. 23, 2020 1:08 PM ETMerck & Co., Inc. (MRK)By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3647078-merck-a2-bio-in-development-pact-for-allogeneic-cell-therapy-candidates-for-cancer



Our Science Accessing a new class of targets "Targets lost" in tumor cells

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

image811

 BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER 

Dec 22, 2020 PDF Version

WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 22, 2020--

 Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit from biomarker-driven therapies.


 For more information, go to www.bayer.us. 


 For more information, please visit www.veracyte.com

https://www.veracyte.com/  


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005138/en/ 

 

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

Tue December 22, 2020 8:15 AM|Business Wire|About: VCYT

WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)-- Bayer and Veracyte (VCYT) (Nasdaq: VCYT)

https://seekingalpha.com/pr/18131845-bayer-and-veracyte-announce-precision-oncology-collaboration-in-thyroid-cancer


https://seekingalpha.com/symbol/VCYT


https://seekingalpha.com/symbol/BAYZF

 

Veracyte and Bayer collaborate in precision oncology; 

Dec. 22, 2020 11:34 AM ET

Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, 

SA News Editor 

https://seekingalpha.com/news/3646727-veracyte-and-bayer-collaborate-in-precision-oncology-shares-jumpplus-17



PIPELINE Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other diseases

Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

image812

 

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

DOWNLOAD AS PDFDECEMBER 17, 2020

- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -

- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.


 About Voclosporin
Voclosporin is a novel therapy in development for patients with LN, an inflammation of the kidney which is one of the most serious complications of the autoimmune disease SLE. If left untreated, LN can lead to irreversible kidney damage, kidney failure or even death. Through an extensive clinical program, voclosporin has demonstrated superiority to the standard-of-care for LN. 


 

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Thu December 17, 2020 4:00 AM|Business Wire|About: AUPH

- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -

- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH) 

https://seekingalpha.com/pr/18126413-aurinia-announces-collaboration-and-licensing-agreement-otsuka-pharmaceutical-co-ltd-for


 Learn more about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005216/en/ 


https://www.auriniapharma.com/


https://seekingalpha.com/symbol/AUPH


https://www.otsuka.co.jp/en/



Changing the course of autoimmune disease

Lilly Announces Agreement to Acquire Prevail Therapeutics

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

Lilly Announces Agreement to Acquire Prevail Therapeutics

image813

 

Lilly Announces Agreement to Acquire Prevail Therapeutics

December 15, 2020Download PDFAcquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease

INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.


 To learn more about Lilly, please visit us at www.lilly.com.  


https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-prevail-therapeutics-301192753.html


https://www.prevailtherapeutics.com/our-science/#overview


https://seekingalpha.com/symbol/LLY


OUR SCIENCE We are pioneering the development of novel gene therapies that target the root genetic causes of Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, ALS, and other neurodegenerative disorders.

Veracyte broadens the collaboration with JNJ

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

Lilly Announces Agreement to Acquire Prevail Therapeutics

image814

 VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON<

 Dec 15, 2020 PDF Version

Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.

 

Veracyte broadens the collaboration with JNJ in early cancer detection

Dec. 15, 2020 9:49 AM ET Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3644460-veracyte-broadens-collaboration-jnj-in-early-cancer-dete


https://seekingalpha.com/symbol/VCYT


https://seekingalpha.com/symbol/JNJ


 For more information, please visit www.veracyte.com 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005345/en/ 

 

PIPELINE

Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease

https://www.veracyte.com/our-products/pipeline




PIPELINE Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

image815

 

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore

DECEMBER, 14, 2020

- Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development

LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that they have jointly formed a new company, Overland ADCT BioPharma (CY) Limited, to develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore. Overland Pharmaceuticals has invested $50 million in Overland ADCT BioPharma to fund operations, including development plans for approval of Lonca for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the licensed territory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005195/en/


 For more information, please visit https://adctherapeutics.com/  

https://seekingalpha.com/symbol/ADCT


https://www.overlandpharma.com/

 

OUR PIPELINE

https://www.overlandpharma.com/our-pipeline/



https://seekingalpha.com/pr/18120747-adc-therapeutics-and-overland-pharmaceuticals-announce-formation-of-overland-adct-biopharma

OUR PIPELINE

AstraZeneca buying Alexion in $39B cash and stock deal

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma

image816


AstraZeneca Agrees to Buy Alexion for $39 Billion

The deal would bolster the British drug giant’s footprint in rare diseases 

By Jenny Strasburg   and Joseph Walker

Updated Dec. 12, 2020 12:27 pm ET 

 LONDON— AstraZeneca AZN 0.71% PLC said it agreed to buy Boston-based Alexion Pharmaceuticals Inc. ALXN 1.78% for $39 billion in cash and stock, a move that would bolster the British drug giant’s footprint in rare diseases. 

 

AstraZeneca to acquire Alexion bulking up rare disease portfolio

Dec. 12, 2020 11:52 AM ET

AstraZeneca PLC (AZN) By: Dulan Lokuwithana, SA News Editor 

https://seekingalpha.com/news/3643893-astrazeneca-to-acquire-alexion-bulking-up-rare-disease-portfolio


https://seekingalpha.com/symbol/AZN


https://seekingalpha.com/symbol/ALXN


https://alexion.com/our-research/pipeline


 Accelerating AstraZeneca’s strategic and financial development AstraZeneca to acquire Alexion This webinar and conference call for investors and analysts is being recorded 12 December 2020 

https://www.astrazeneca.com/content/dam/az/PDF/2020/20201212_Call_Alxn_Cmb_prsn.pdf?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link


PIPELINE Advancing Our Pipeline Every Day

Gilead Sciences to Acquire MYR GmbH Thu December 10, 2020 8:00 AM|Business Wire|About: GILD

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

image817

 

December 10, 2020

Gilead Sciences to Acquire MYR GmbH

– Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction –

– Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021 –

– Acquisition Builds on Gilead’s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV –

FOSTER CITY, Calif. & BAD HOMBURG, Germany--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company f


 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005315/en/


 Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com. 


 For more information on MYR, please visit the company's website at www.myr-pharma.com. 


 For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 


 

Gilead Sciences to Acquire MYR GmbH

Thu December 10, 2020 8:00 AM|Business Wire|About: GILD 

https://seekingalpha.com/pr/18117705-gilead-sciences-to-acquire-myr-gmbh


https://seekingalpha.com/symbol/GILD


MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. The company’s lead compound Bulevirtide (formerly known as Myrcludex B) is a first-in-class entry inhibitor for treatment of chronic HBV and HDV and is currently in a Phase 3 study in the indication of chronic HDV.

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing

image818

 Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.


https://corporate.thermofisher.com/en/home.html


https://www.thermofisher.com/us/en/home.html


 

Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing

Wed December 9, 2020 8:00 AM|PR Newswire

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.

https://seekingalpha.com/pr/18115833-thermo-fisher-scientific-expands-global-footprint-for-drug-product-development-and-commercial


 For more information, please visit www.thermofisher.com. 

https://seekingalpha.com/symbol/TMO


 

Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China

Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO 

https://seekingalpha.com/pr/18074732-thermo-fisher-scientific-and-innoforce-partner-to-establish-biologics-and-steriles-drug


  For more information, please visit www.innoforcepharma.com. 



Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO PR Newswire WALTHAM, Mass. and SHANGHAI, Nov. 6, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022.

BiotechVortex™

中国生物制药向科兴中维注资5.15亿美元,持股15.03% 2020-12-7

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

image819

 Companies

Sino Biopharm secures room for future growth with US$515 million investment in Sinovac’s Covid-19 vaccine unit

Beijing-based generic drug maker buys 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech
Deal comes ahead of major announcement from China to launch 600 million doses of Covid-19 vaccines for use this year

Eric Ng Published: 3:18pm, 7 Dec, 2020


http://www.sinobiopharm.com/index.html#/


http://www.sinovac.com/


 

中国生物制药向科兴中维注资5.15亿美元,持股15.03%

2020-12-7

2020年12月7日,中国生物制药发布公告称,连同其附属公司的全资附属公司香港俊领有限公司就以5.15亿美元向北京科兴中维生物技术有限公司(简称科兴中维)出资订立协议。于出资完成后,中国生物制药将于科兴中维的注册资本中拥有15.03%权益。科兴中维将于中国生物制药的财务报表中入账列为联营公司。

http://www.sinobiopharm.com/index.html#/news/newsdeatil?id=2630


 

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

image820


  • Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

Dec 04, 2020PDF Version

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)

 

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment ofRead moreDec 04, 2020 

 

Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

Dec. 04, 2020 9:30 AM ETY-mAbs Therapeutics, Inc. (YMAB)By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3641765-y-mabs-inks-distribution-pact-takeda-for-nerve-cell-cancer-meds-danyelza-omburtamab


https://seekingalpha.com/symbol/YMAB


https://www.takeda.com/en-us

https://seekingalpha.com/symbol/TAK

 

About the Y-mAbs development pipeline of therapies

https://ymabs.com/research-development/pipeline/



About the Y-mAbs development pipeline of therapies

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

image821

 

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Thu December 3, 2020 3:00 AM|PR Newswire

  • Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets
  • Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target 
  • Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases 

DARMSTADT, Germany, CAMBRIDGE, UK and NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.



 www.artiospharma.com 


 View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in-oncology-301185247.html 


https://seekingalpha.com/symbol/MKGAY


https://www.artiospharma.com/science/#pipeline


https://www.emdgroup.com/en

 

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

December 3, 2020
 

Our pipeline Working with its collaborators, Artios is drugging novel protein classes across a range of DDR pathways. Artios has in-licensed two lead programmes from Cancer Research Technology, which target proteins that control key aspects of DNA repair and other cellular processes.

Bioengineered Antibody-Toxin Fusion Proteins- FastPharming® System

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel

image822

 

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

Tue December 1, 2020 4:30 PM | Globe Newswire | About: IBIO

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSEA:IBIO) 

 

Bioengineered Antibody-Toxin Fusion Proteins

 

New line of attack against cancer

atbodies are differentiated by both their unique composition and novel mechanism of action, providing a new class of biologic as an innovative therapeutic solution for hard-to-treat and refractory cancer.

https://www.atbtherapeutics.com/atbody


 under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. 


 FastPharming® System 

 

FastPharming®

Advantages of Plant Based Protein Production

https://www.ibioinc.com/technology/fastpharming


 For more information, visit www.ibioinc.com. 


https://seekingalpha.com/symbol/IBIO


 For more information, visit www.atbtherapeutics.com. 



iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins Download as PDFDECEMBER 01, 2020 4:30PM EST BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

image823

 

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

Wed December 2, 2020 7:00 AM|PR Newswire|About: BDX

- Investment includes new manufacturing facility in Europe

FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)


 The new manufacturing facility in Europe is expected to be operational by the end of 2023. 


 For more information on BD, please visit bd.com. 



 View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183330.html 


 

12/02/2020

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years


https://seekingalpha.com/news/3640859-becton-dickinson-to-invest-1_2b-in-pre-fillable-syringe-manufacturing-capacity


https://seekingalpha.com/symbol/BDX


BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years PDF Version Investment includes new manufacturing facility in Europe FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX),

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract

 

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

Wed December 2, 2020 8:00 AM|Business Wire|About: TLRY

BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)-- Tilray, Inc. (TLRY) (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.


 "With Hormosan we have gained a partner that has excellent expertise and contacts in the field of pain therapy and neurology and will thus significantly increase the visibility of Tilray's full-spectrum cannabis extracts in the future," explains Sascha Mielcarek, Managing Director Europe at Tilray. “This will give physicians and patients even better access to our medical cannabis extracts while supporting our goal of contributing to improved care for patients with medical cannabis." 

https://www.hormosan.com/


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005128/en/ 

 

HORMOSANSeltene Erkrankungen
in der Neurologie

https://www.hormosan.com/seltene_erkrankungen.html 

 

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

BERLIN & FRANKFURT, Germany --(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum
December 2, 2020


https://www.tilray.com/

https://seekingalpha.com/symbol/TLRY


https://ir.tilray.com/news-releases/news-release-details/tilray-inc-and-hormosan-sign-cooperation-agreement-promotion


Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany December 2, 2020 at 8:00 AM EST PDF Version BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

image824

 

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Wed December 2, 2020 8:00 AM|PR Newswire|About: ABBV

- Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration

PR Newswire

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp.,



 For more information, visit www.frontiermeds.com  


 For more information about AbbVie, please visit us at www.abbvie.com. 


https://seekingalpha.com/symbol/ABBV


 

Science

https://frontiermeds.com/science/#chemoproteomics


 Dec 02, 2020

AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.


December 2, 2020 AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets Sign Up for Alerts Print - Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases - Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV)

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

image825

 

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Fri November 27, 2020 7:30 AM|Business Wire|About: BIIB, SAGE

  • Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.
  • Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea
  • Sage Therapeutics (SAGE) to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone payments, profit sharing and royalties
  • Sage to host conference call Monday, November 30 at 8:00 a.m. ET
  • Biogen to host conference call Monday, November 30 at 9:00 a.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201127005340/en/


 Zuranolone is a next-generation positive allosteric modulator of the gamma-aminobutyric acid (GABAA) receptor. The GABAA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. This mechanism of action is a novel approach that may enable a new class of antidepressants. 


 We routinely post information that may be important to investors on our website at www.biogen.com. 

https://seekingalpha.com/symbol/BIIB


 For more information, please visit www.sagerx.com. 

https://seekingalpha.com/symbol/SAGE

https://www.sagerx.com/programs-research/pipeline/



 

November 27, 2020

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders



Pipeline Advancing a Leading Brain Health Portfolio Our differentiated approach to drug discovery and development has allowed us to create a broad portfolio of fully-owned product candidates with the potential for development in a wide range of psychiatric, neurological and related central nervous system (CNS) disorders.

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

image826

 

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Wed November 25, 2020 7:45 AM|GlobeNewswire|About: BNTX

  • Long-term collaboration underpins BioNTech’s strategy to leverage Artificial Intelligence (AI) and Machine Learning (ML) technologies to support the discovery and development of novel immunotherapies based on InstaDeep’s DeepChainTM technology platform
  • BioNTech (NTGN) and InstaDeep to establish a joint AI Innovation Lab to advance a portfolio of enterprise-wide digital initiatives in the areas of drug discovery and design, protein engineering, and operations

MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd

 For more information, please visit www.BioNTech.de. 

 To learn more, please visit www.instadeep.com. 

https://seekingalpha.com/symbol/BNTX

Research

InstaDeep’s in-house research team contributes to the latest advancements in AI – from the fundamentals of machine learning to robotics and deep reinforcement learning. Our published research has been presented at world-leading conferences such as NeurIPS 2018.

https://www.instadeep.com/research/

25 November 2020

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation ..

OPEN 

Pipeline

Schrödinger Announces a Collaboration with Bristol Myers Squibb

Schrödinger Announces a Collaboration with Bristol Myers Squibb

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel

image827

 

Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb

Mon November 23, 2020 6:30 AM|Business Wire|About: BMY, SDGR

Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.


 To learn more, visit www.schrodinger.com  


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005663/en/ 


https://seekingalpha.com/symbol/SDGR


https://seekingalpha.com/symbol/BMY


 

Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb

https://seekingalpha.com/news/3638576-schrodinger-inks-multi-target-drug-discovery-deal-bristol-myers-squibb


https://www.schrodinger.com/pipeline




OUR VISION IN ACTION Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

OneOncology Partners with Genentech

Schrödinger Announces a Collaboration with Bristol Myers Squibb

OneOncology Partners with Genentech

image828

 

OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites

Mon November 23, 2020 6:15 AM|PR Newswire|About: RHHBY

MyTACTIC Precision Basket Trial is Scheduled to Launch in December 2020 at Community Oncology Centers Including OneOncology

PR Newswire

NASHVILLE, Tenn., Nov. 23, 2020 /PRNewswire/ -- OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 Genentech's new clinical trial -- Targeting Actionable Mutation Study in Cancer (MyTACTIC) -- aims to match patient populations with a targetable genomic alteration to a specific investigational agent. 


 View original content to download multimedia:http://www.prnewswire.com/news-releases/oneoncology-partners-with-genentech-to-bring-personalized-cancer-research-to-patients-at-community-oncology-sites-301178283.html 


 About OneOncology: 
OneOncology is a national partnership of independent, community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven, technology-powered and patient-centric model. OneOncology is comprised of leading community oncology practices representing over 475 providers practicing at nearly 175 sites of care across the United States. 

https://www.oneoncology.com/


https://www.gene.com/media


https://www.roche.com/


https://seekingalpha.com/symbol/RHHBY




OneR is a national site management organization that brings operational expertise and centralized services to efficiently deliver multi-center clinical research across our growing network of community oncology practices.

Merck to Acquire OncoImmune

Schrödinger Announces a Collaboration with Bristol Myers Squibb

OneOncology Partners with Genentech

image829

 

Merck to Acquire OncoImmune

Save

November 23, 2020 6:45 am EST

Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19

Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19

KENILWORTH, N.J., & ROCKVILLE, Md.--(BUSINESS WIRE)-- Merck (NYSE: MRK)


 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005593/en/ 


 

Merck adds to suite of COVID-19 clinical programs through OncoImmune acquistion

Nov. 23, 2020 6:54 AM ETMerck & Co., Inc. (MRK)By: Gaurav Batavia, SA News Editor 

https://seekingalpha.com/news/3638577-merck-adds-to-suite-of-covidminus-19-clinical-programs-through-oncoimmune-acquistion


https://seekingalpha.com/symbol/MRK


  Visit www.oncoimmune.com. 



OncoImmune’s founders have identified a novel pathway that is a checkpoint for the development of a number of disease indications. Our lead molecule, CD24Fc, targets this pathway and efficiently modulate the immune response in animal models of GVHD, multiple sclerosis and rheumatoid arthritis. We have completed phase II clinical trial for GVHD and is launching a pivotal phase III clinical trial for the indication.

BiotechVortex™

QIAGEN Collaborates with BioNTech on Companion Diagnostics Development

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

image830

 

QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck

Wed November 18, 2020 4:05 PM|Business Wire|About: BNTX, QGEN

  • QIAGEN and BioNTech (NTGN) to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections
  • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics
  • Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005908/en/ 


https://www.qiagen.com/us/

https://seekingalpha.com/symbol/QGEN


https://biontech.de/

https://seekingalpha.com/symbol/BNTX





NOV 18 2020 QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck • QIAGEN and BioNTech to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics • Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing Hilden, Germany and Germantown, Maryland, November 18, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration with BioNTech SE (Nasdaq: BNTX)

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

image831

 

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Thu November 19, 2020 6:45 AM|PR Newswire|About: LLY

BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Ypsomed (YPHDF) (SWX: YPSN)  For the latest updates, visit http://www.lillydiabetes.com/  


 Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes 

https://www.ypsomed.com/en/media/details/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes.html


 Additional information is available under www.ypsomed.com. 


 View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes-301176401.html 


 
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

November 19, 2020

Tags |  Product

BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.


https://seekingalpha.com/symbol/LLY



Injection systems for self-medication

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

image832

 

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

Thu November 19, 2020 7:00 AM|Business Wire|About: PFE

NEW YORK & SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)-- Pfizer, Inc. (PFE) and LianBio 


 For more information, please visit lianbio.com. 


 We routinely post information that may be important to investors on our website at www.pfizer.com.cn. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005290/en/ 


https://www.lianbio.com/pipeline/


https://seekingalpha.com/symbol/PFE


https://seekingalpha.com/news/3637861-pfizer-teams-up-lianbio-for-development-of-novel-therapeutics-in-greater-china



LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates

Ultragenyx to build gene therapy manufacturing facility

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G

image833

 

Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases

Mon November 9, 2020 8:05 AM|GlobeNewswire|About: RARE

State-of-the-art facility to be located in Bedford, Massachusetts

NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.  (RARE)

 

Ultragenyx to build gene therapy manufacturing facility

 Nov. 9, 2020 9:27 AM ET|About: Ultragenyx Pharmaceutical... (RARE)|By: Vandana Singh, SA News Editor  


 For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com. 


https://seekingalpha.com/symbol/RARE



 Nov 9, 2020Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases 

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no typically no approved therapies treating the underlying disease.

Novartis buys Vedere Bio for $280M

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

image834

 

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Thu October 29, 2020 2:15 AM|PR Newswire

$150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million

Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies

PR Newswire

CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis.

 

Novartis buys Vedere Bio for $280M

https://seekingalpha.com/news/3627953-novartis-buys-vedere-bio-for-280m

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-acquires-vedere-bio-a-novel-optogenetics-aav-gene-therapy-company-301162269.html

SOURCE Vedere Bio, Inc.


https://seekingalpha.com/symbol/NVShttps://seekingalpha.com/symbol/NVS


https://www.vederebio.com/

 

Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

Oct 29, 2020

  • Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.

  • Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.

  • Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.

Basel, October 29, 2020

https://www.novartis.com/news/media-releases/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-treating-blindness


Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss $150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies CAMBRIDGE, Mass., October 29, 2020 – Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million.

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

image835

 

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Wed October 28, 2020 7:00 AM|Business Wire|About: BMY

insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion

Collaboration to Advance Targets and Therapeutic Candidates

SAN FRANCISCO--(BUSINESS WIRE)-- insitro


 For more information on insitro, please visit the company’s website at www.insitro.com. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005276/en/ 

 

Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders

 Oct. 28, 2020 7:26 AM ET|About: Bristol-Myers Squibb Company (BMY)|By: Vandana Singh, SA News Editor 

https://seekingalpha.com/news/3627107-insitro-inks-five-year-pact-bristol-myers-for-neurodegenerative-disorders


https://seekingalpha.com/symbol/BMY


Leading the way to better medicines through predictive models, created by machine learning and biology at scale.

Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

image836

 

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

Mon October 26, 2020 7:30 AM|PR Newswire|About: JAZZ, SWTX

Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks' Strategic Focus on Targeted Oncology

Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million

PR Newswire

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and SpringWorks Therapeutics, Inc. (SWTX)


 For more information, please visit www.jazzpharmaceuticals.com  


 For more information, visit www.springworkstx.com  


 View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-acquires-springworks-therapeutics-faah-inhibitor-program-301159303.html 


https://www.springworkstx.com/pipeline/


https://www.jazzpharma.com/science/pipeline/


https://seekingalpha.com/symbol/JAZZ


https://seekingalpha.com/symbol/SWTX


 

October 26, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program

PDF Version



Pipeline SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs being evaluated as standalone and combination therapies. Our development programs include two potentially registrational clinical trials in rare tumor types as well as several other programs addressing highly prevalent, genetically defined cancers. Our team is working with urgency on behalf of the underserved patients living with these devastating illnesses.

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

image837

 

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

Fri October 23, 2020 8:00 AM|GlobeNewswire|About: RARE, SLDB

-Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and variants-

-Solid receives $40 million upfront via equity investment at a premium; up to $255 million in milestones plus royalty payments-

-Solid retains exclusive rights to all other uses of its microdystrophins, including its existing SGT-001 program-

NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)


 For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com. 


 For more information, please visit www.solidbio.com. 


https://seekingalpha.com/symbol/RARE


https://www.ultragenyx.com/pipeline/


 Toggle Summary Oct 23, 2020Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy 

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no typically no approved therapies treating the underlying disease.

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

image838

 

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

Mon October 12, 2020 4:05 PM|GlobeNewswire|About: ATNX

BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered into a research collaboration with PharmaEssentia Corporation (Taipei Exchange: 6446). 


 For more information, please visit: www.axistherapeutics.com. 


 For more information, please visit www.pharmaessentia.com . 


 For more information about XPH, visit www.xphcn.com. 


 For more information, please visit www.athenex.com. 


https://seekingalpha.com/symbol/ATNX


 

Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy

Oct. 12, 2020 4:20 PM ET|About: Athenex, Inc. (ATNX)|By: Vandana Singh, SA News Editor  

https://seekingalpha.com/news/3621525-axis-therapeutics-inks-research-pact-pharmaessentia-for-cancer-t-cell-therapy



Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

image839

 

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, Including Amyotrophic Lateral Sclerosis

Tue October 6, 2020 10:00 AM|Business Wire|About: BIIB

Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegeneration

ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. (BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).


 To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com 


 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005506/en/


https://www.scribetx.com/


https://seekingalpha.com/symbol/BIIB

Scribe is building and applying a suite of CRISPR technologies designed for therapeutic use into a single continually evolving and expanding genetic modification platform. We are rapidly generating hundreds of synthetic CRISPR molecules and novel technologies every month and folding the best into a fully integrated set of genome editing modalities.

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

image840

 

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

Tue October 6, 2020 8:00 PM|PR Newswire|About: IVBIY

SAN FRANCISCO and SUZHOU, China, Oct. 6, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (IVBIY) ("Innovent") (HKEX: 01801)


 For more information, please visit: www.innoventbio.com. 


 View original content:http://www.prnewswire.com/news-releases/innovent-announces-the-effectiveness-of-the-expanded-global-collaboration-with-lilly-on-tyvyt-sintilimab-injection-following-the-expiration-of-hsr-act-waiting-period-301146892.html 


 

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

Oct. 7, 2020 12:38 AM ET|About: Innovent Biologics, Inc. (IVBIY)|By: Mamta Mayani, SA News Editor  

https://seekingalpha.com/news/3620325-innovent-bios-expanded-collaboration-lilly-for-tyvyt-now-effective


http://innoventbio.com/en/#/product/products


https://seekingalpha.com/symbol/LLY

PRODUCT CENTER Innovent has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT® has been the only PD-1 inhibitor included in the NRDL since 2019. Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.

Takeda and Arrowhead Pharmaceuticals team up in rare liver disease

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

image841

 

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Thu October 8, 2020 7:30 AM|Business Wire|About: ARWR, TAK

−        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD

−        Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M

−        Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda (TKPHF) and Arrowhead under a 50/50 profit-sharing structure

−        Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.

−        Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (ARWR) 


 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/


 For more information, visit https://www.takeda.com. 

https://www.takeda.com/investors/


 For more information, please visit www.arrowheadpharma.com 


https://seekingalpha.com/symbol/ARWR

 

Pipeline

Novel Drugs to
Treat Intractable Diseases

https://arrowheadpharma.com/pipeline/

 

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

October 8, 2020 Osaka, JAPAN, and Pasadena, CALIF.

  • Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
  • Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
  • Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure
  • Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
  • Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) 

https://www.takeda.com/newsroom/newsreleases/2020/takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-foralpha-1-antitrypsin-associated-liver-disease/

Pipeline Novel Drugs to Treat Intractable Diseases

BiotechVortex™

Bristol Myers Squibb to acquire Myokardia for $13.1B in cash

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

image842

 

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mon October 5, 2020 6:30 AM|Business Wire|About: BMY, MYOK

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (MYOK)


 For more information about Bristol Myers Squibb, visit us at BMS.com  


  www.myokardia.com 


 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005381/en/


 

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

10/05/2020CATEGORY: 

  • Corporate/Financial News

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.

https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx


https://seekingalpha.com/symbol/MYOK


https://seekingalpha.com/symbol/BMY



MyoKardia

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

image843

 

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Tue September 29, 2020 11:22 PM|Business Wire|About: LGND, PFE

  • Pfizer (PFE) to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
  • CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
  • CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China

SUZHOU, China--(BUSINESS WIRE)-- CStone Pharmaceuticals (CSPHF) (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc.)


 For more information about CStone, please visit: www.cstonepharma.com. 


http://www.cstonepharma.com/en/


 For more information, please visit www.pfizer.com.cn. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/ 


https://seekingalpha.com/symbol/PFE


https://seekingalpha.com/symbol/CSPHF


 CSTONE PHARMACEUTICALS - B (2616) 

https://www.hkex.com.hk/Market-Data/Securities-Prices/Equities/Equities-Quote?sym=2616&sc_lang=en



CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China Times:2020.09.30 Author:CStone Pfizer to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China (SUZHOU, China, Sept 30, 2020) CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc. (NYSE: PFE)) announced today the formation of a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.

Roche doubles down on promising inflammation field with Inflazome buy

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Roche doubles down on promising inflammation field with Inflazome buy

image844

 

Inflazome Announces Acquisition by Roche

Mon September 21, 2020 2:00 AM|Business Wire|About: RHHBY

  • Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
  • Acquisition of Inflazome gives Roche (RHHBY) full rights to the Inflazome portfolio
  • Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
  • Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments

DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/ 


https://www.cell.com/fulltext/S0092-8674%2810%2900075-9


https://seekingalpha.com/symbol/RHHBY


 

Roche doubles down on promising inflammation field with Inflazome buy

Sep. 26, 2020 12:30 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor  

https://seekingalpha.com/news/3616633-roche-doubles-down-on-promising-inflammation-field-inflazome-buy



Biotech Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field by Nick Paul Taylor | Sep 21, 2020 5:38am

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Roche doubles down on promising inflammation field with Inflazome buy

image845

 

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Wed September 23, 2020 2:00 AM|Business Wire|About: PFE

PARIS & NEW YORK--(BUSINESS WIRE)-- Vivet Therapeutics 


 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005790/en/ 


 Please visit us on www.vivet-therapeutics.com  


 

PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS

Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease

Pfizer acquires 15% ownership stake in Vivet

Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),

https://www.vivet-therapeutics.com/en/news-events/latest/pfizer-secures-exclusive-option-to-acquire-gene-therapy-company-vivet-therapeutics


https://seekingalpha.com/symbol/PFE



Product Pipeline

Pepinemab in Combination with KEYTRUDA

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

image846


Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Thu September 17, 2020 8:00 AM|GlobeNewswire|About: VCNX

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX)


http://www.vaccinex.com/



Vaccinex partners with Merck in cancer

Sep. 17, 2020 8:31 AM ET|About: Vaccinex, Inc. (VCNX)|By: Mamta Mayani, SA News Editor  .com/news/3614927-vaccinex-partners-merck-in-cancer

https://seekingalpha.com/news/3614927-vaccinex-partners-merck-in-cancer


http://www.vaccinex.com/pipeline/pepinemab-immuno-oncology/


https://seekingalpha.com/symbol/VCNX



 Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX)

http://ir.vaccinex.com/news-releases/news-release-details/vaccinex-announces-clinical-collaboration-merck-evaluate




Pepinemab Immuno-Oncology First in class, anti-SEMA4D immunotherapy for cancer.

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

image847

 

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Thu September 17, 2020 8:30 AM|Accesswire|About: DYAI

LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE / September 17, 2020 / Dyadic International, Inc. (DYAI) ("Dyadic" or the "Company") (NASDAQ:DYAI)


 Please visit Dyadic's website at http://www.dyadic.com for additional information 


 please visit http://www.hrs.com.cn/index.html. 


http://www.hrs.com.cn/index.html


https://www.hengruitx.com/


 

Dyadic teams up with Jiangsu Hengrui for biologic drug development

Sep. 17, 2020 9:05 AM ET|About: Dyadic International, Inc. (DYAI)|By: Mamta Mayani, SA News Editor  

https://seekingalpha.com/news/3614955-dyadic-teams-up-jiangsu-hengrui-for-biologic-drug-development


  http://www.dyadic.com/. 


https://seekingalpha.com/symbol/DYAI


https://www.hengruitx.com/rd.html#Htipipe

HTI U.S. / GLOBAL CLINICAL STUDIES

BiotechVortex™

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

image848

 

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Thu September 17, 2020 6:30 AM|PR Newswire|About: AMGN, LLYPR Newswire

INDIANAPOLIS and THOUSAND OAKS, Calif., Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Amgen (AMGN)


 For more information, visit www.amgen.com  


 To learn more about Lilly, please visit us at lilly.com 


https://www.prnewswire.com/news-releases/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies-301132807.html


https://seekingalpha.com/symbol/AMGN


https://seekingalpha.com/symbol/LLY


https://www.lilly.com/discovery/clinical-development-pipeline

Medicines in Development Molecule & Potential Indication Data as of July 28, 2020 Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com

Takeda Opens New R&D Cell Therapy Manufacturing Facility

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

image849

 

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

Tue September 15, 2020 7:30 AM|Business Wire|About: TAK

  • cGMP Facility Builds Takeda’s Leadership Capabilities in Cell Therapy and Increases its Capacity to Supply Innovative Cell Therapies for Global Clinical Trials
  • Five Collaborative Oncology Cell Therapy Programs Expected to be in Clinical Development by the End of FY2021

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) 


https://www.takeda.com/


 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005224/en/ 


 For more information, visit https://www.takeda.com. 


https://seekingalpha.com/symbol/TAK



Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs September 15, 2020 Osaka, JAPAN cGMP Facility Builds Takeda’s Leadership Capabilities in Cell Therapy and Increases its Capacity to Supply Innovative Cell Therapies for Global Clinical Trials Five Collaborative Oncology Cell Therapy Programs Expected to be in Clinical Development by the End of FY2021 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)

Moderna builds footprint outside U.S. in Switzerland

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Moderna builds footprint outside U.S. in Switzerland

image850

 

Moderna Announces First Commercial Organization Outside North America in Switzerland

Wed September 16, 2020 5:00 AM|Business Wire|About: MRNA

Dan Staner appointed as Vice President and Managing Director, Switzerland

Reinforces Moderna’s commitment to Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA), (Nasdaq: MRNA)


 To learn more, visit www.modernatx.com. 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005315/en/ 


https://seekingalpha.com/symbol/MRNA


 

Moderna builds footprint outside U.S. in Switzerland

https://seekingalpha.com/news/3614438-moderna-builds-footprint-outside-u-s-in-switzerland


Moderna Announces First Commercial Organization Outside North America in Switzerland September 16, 2020 at 5:00 AM EDT PDF Version Dan Staner appointed as Vice President and Managing Director, Switzerland Reinforces Moderna’s commitment to Europe CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 16, 2020-- Moderna, Inc., (Nasdaq: MRNA)

Seattle Genetics teams up with Merck in cancer

SpringWorks teams up with Janssen in multiple myeloma study

Moderna builds footprint outside U.S. in Switzerland

image851

 

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

Mon September 14, 2020 6:45 AM|Business Wire|About: MRK, SGEN

Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck (MRK) to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock

Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe

Seattle Genetics (SGEN) to Host Conference Call Today at 9:00 a.m. ET

BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck, known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005237/en/


https://seekingalpha.com/symbol/MRK


https://seekingalpha.com/symbol/SGEN

 

Seattle Genetics teams up with Merck in cancer

https://seekingalpha.com/news/3613576-seattle-genetics-teams-up-merck-in-cancer


 Seattle Genetics website at www.seattlegenetics.com


https://www.seattlegenetics.com/pipeline/tisotumab-vedotin 


 For more information, visit www.merck.com 


 For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.  





Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations 09/14/2020 Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe Seattle Genetics to Host Conference Call Today at 9:00 a.m. ET BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

SpringWorks teams up with Janssen in multiple myeloma study

SpringWorks teams up with Janssen in multiple myeloma study

SpringWorks teams up with Janssen in multiple myeloma study

image852

 

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

Mon September 14, 2020 6:30 AM|GlobeNewswire|About: SWTXGlobeNewswire

STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX)


 

SpringWorks teams up with Janssen in multiple myeloma study

https://seekingalpha.com/news/3613550-springworks-teams-up-janssen-in-multiple-myeloma-study


https://seekingalpha.com/symbol/SWTX


https://seekingalpha.com/symbol/JNJ


 For more information, please visit www.springworkstx.com 


https://www.springworkstx.com/pipeline/nirogacestat/


 

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

September 14, 2020 at 6:30 AM EDTPDF Version

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX

https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-clinical-collaboration


Nirogacestat (Gamma Secretase Inhibitor) Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor (GSI) in Phase 3 clinical development for patients with desmoid tumors. Gamma secretase is a protease complex that cleaves, or divides, multiple transmembrane protein complexes, including Notch, which, when dysregulated, can play a role in activating pathways that contribute to desmoid tumor growth.

Gilead nears deal to buy cancer drug maker for $20bn

SpringWorks teams up with Janssen in multiple myeloma study

SpringWorks teams up with Janssen in multiple myeloma study

image853

 

Gilead nears $20B-plus deal to buy Immunomedics - WSJ

Sep. 12, 2020 3:31 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Carl Surran, SA News Editor  


 

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

Biotech drugmaker has a market value of roughly $10 billion

By Cara Lombardo and Jonathan D. RockoffUpdated Sept. 12, 2020 3:31 pm ET 

https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777


https://seekingalpha.com/symbol/GILD


https://www.bloomberg.com/news/articles/2020-09-13/gilead-said-to-near-immunomedics-bid-worth-more-than-20-billion?srnd=deals


https://www.gilead.com/


 

Gilead to buy Immunomedics for $21B, bolstering its cancer arsenal

Sep. 13, 2020 4:32 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Liz Kiesche, SA News Editor 

https://seekingalpha.com/news/3613503-gilead-to-buy-immunomedics-for-21b-bolstering-cancer-arsenal


 

September 13, 2020

Gilead Sciences to Acquire Immunomedics

-- Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors --

-- Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential --

-- Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline, Building on Agreements Executed Earlier This Year --

-- Immunomedics to Present Latest Clinical Findings on Trodelvy at European Society for Medical Oncology Virtual Congress 2020 This Coming Week --

FOSTER CITY, Calif. & MORRIS PLAINS, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU)

https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics



Gilead nears deal to buy cancer drug maker for $20bn Offer is worth close to double New Jersey-based Immunomedics’ market value James Fontanella-Khan, Ortenca Aliaj and Hannah Kuchler SEPTEMBER 12 2020

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

image854

 

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

Fri September 4, 2020 7:00 AM|PR Newswire|About: ABBV, IMAB

I-Mab to receive upfront payment of USD180 million

Potential to explore combination therapies with I-Mab's lemzoparlimab and AbbVie's venetoclax (Venclexta®)

I-Mab to host call for investors on September 4 at 8:00 am ET

PR Newswire

NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (IMAB)


 For more information, please visit http://ir.i-mabbiopharma.com 


 For more information about AbbVie, please visit us at www.abbvie.com. 


https://www.prnewswire.com/news-releases/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncology-therapy-301124424.html


https://seekingalpha.com/symbol/IMAB


https://seekingalpha.com/symbol/ABBV


https://www.i-mabbiopharma.com/en/Pipeline.aspx


 

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie and I-Mab to collaborate on development and commercialization of I-Mab’s highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)

I-Mab to receive upfront payment of USD180 million

Potential to explore combination therapies with I-Mab’s lemzoparlimab and AbbVie’s venetoclax (Venclexta®)

I-Mab to host call for investors on September 4 at 8:00am ET

NORTH CHICAGO, Illinois and SHANGHAI, China, September 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB)

https://www.i-mabbiopharma.com/en/article-564.aspx



Pipeline Strategy and Progress

ACE2-Fc is a recombinant protein

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

image855

 

iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic

Fri August 28, 2020 7:15 AM|GlobeNewswire|About: IBIOGlobeNewswire

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (“Planet”) for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.


 https://www.ibioinc.com/therapeutics-and-vaccines/human-and-animal-health-internal-pipeline 


 https://www.planetbiotechnology.com/products.html 


 https://ir.ibioinc.com/press-releases/detail/134/ibio-and-planet-biotechnology-enter-into-exclusive 


 For more information, visit www.ibioinc.com. 


 https://seekingalpha.com/symbol/IBIO 



Human and Animal Health Internal Pipeline

AbbVie teams up with Harvard in viral infection research

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie teams up with Harvard in viral infection research

image856

 August 25, 2020

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

 NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Harvard University  

 

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

Tue August 25, 2020 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (ABBV) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) 


 https://hms.harvard.edu/ 


  For more information about AbbVie, please visit us at www.abbvie.com. 


 For more information, please visit https://otd.harvard.edu. 


 View original content:http://www.prnewswire.com/news-releases/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases-301117726.html 


 

AbbVie teams up with Harvard in viral infection research

Aug. 25, 2020 8:39 AM ET|About: AbbVie Inc. (ABBV)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3608508-abbvie-teams-up-harvard-in-viral-infection-research 


 https://news.abbvie.com/news/press-releases/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases.htm 


 https://seekingalpha.com/symbol/ABBV 



Joining Forces Harvard University, AbbVie form research alliance to address emergent viral diseases August 25, 2020 Research

Bristol-Myers Squibb to acquire protein engineer Forbius

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

AbbVie teams up with Harvard in viral infection research

image857

 

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Mon August 24, 2020 6:59 AM|Business Wire|About: BMY

Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis

NEW YORK & MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company


 https://www.bms.com/ 


 https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-enters-agreement-acquire-forbius-adding-l 


 View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005159/en/ 


 

Bristol-Myers Squibb to acquire protein engineer Forbius

Aug. 24, 2020 7:12 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3608089-bristol-myers-squibb-to-acquire-protein-engineer-forbius 


 https://seekingalpha.com/symbol/BMY 


 

Novel biologics
for treatment of
fibrosis & cancer

 https://forbius.com/ 


 https://forbius.com/#pipeline 



Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis CATEGORY: CORPORATE/FINANCIAL NEWS MONDAY, AUGUST 24, 2020 6:59 AM EDT NEW YORK & MONTREAL--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases,

Merck finds London site for £1B research, business hub

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

image858

 

Merck finds London site for £1B research, business hub

Aug. 18, 2020 3:52 AM ET|About: Merck & Co., Inc. (MRK)|By: Liz Kiesche, SA News Editor  



 

Merck to build £1B London R&D hub for its first ex-U.S. early research center

by Ben Adams | Aug 18, 2020 4:23am 

 https://www.fiercebiotech.com/biotech/merck-to-build-ps1-billion-london-r-d-hub-for-its-first-ex-u-s-early-research-center 


 “We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure,” said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times. 

Our pipeline at a glance Updated July 31, 2020. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

image859

 

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Wed August 12, 2020 8:00 AM|Accesswire

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (HBPC) (TSX:HBP) 


 

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Wednesday, August 12, 2020 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP)

 https://www.accesswire.com/601224/Helix-BioPharma-Corp-and-Moffitt-Cancer-Center-Extend-Immunotherapy-Collaboration 


 https://www.helixbiopharma.com/ 


 https://moffitt.org/ 


 https://www.helixbiopharma.com/pipeline/ 


 https://seekingalpha.com/symbol/HBPCF 


 12 August 2020

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) 

 https://www.helixbiopharma.com/helix-biopharma-corp-and-moffitt-cancer-center-extend-immunotherapy-collaboration/ 



DOS47 Drug Candidates Our most advanced Tumor Defence Breaker L-DOS47 is currently in clinical trials for the treatment of small cell lung cancer (NSCLC) and pancreatic cancer. A second DOS47 candidate, known as V-DOS47, targets the vascular epithelial growth factor receptor 2 and is at preclinical development.

BiotechVortex™

Sarepta Therapeutics and University of Florida Announce Collaboration

Sarepta Therapeutics and University of Florida Announce Collaboration

Sarepta Therapeutics and University of Florida Announce Collaboration

image860

 

Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases

Tue August 11, 2020 8:30 AM|GlobeNewswire|About: SRPT 

 CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. 


 http://www.ufl.edu/ 


 please visit www.sarepta.com 


 https://www.sarepta.com/products-pipeline 


 https://seekingalpha.com/symbol/SRPT 

At Sarepta, we are working with urgency to develop breakthrough therapies to treat genetic diseases. Currently, we have more than 40 investigational therapies in various stages of development—many already in late-stage clinical trials. In many cases, development is being accelerated by our gene therapy engine, which potentially provides a more efficient model for drug design.

Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited

Sarepta Therapeutics and University of Florida Announce Collaboration

Sarepta Therapeutics and University of Florida Announce Collaboration

image861

 

Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited, Extending the Cooperation since 2017

Tue August 4, 2020 7:12 AM|PR Newswire|About: ZCMD

SHANGHAI, Aug. 4, 2020 /PRNewswire/ -- Zhongchao Inc. (ZCMD)


 More information about the Company can be found at its investor relations website at http://izcmd.com. 


 https://www.prnewswire.com/news-releases/zhongchao-inc-renews-contract-with-johnson--johnson-china-limited-extending-the-cooperation-since-2017-301105575.html 


 https://seekingalpha.com/symbol/ZCMD 


 https://seekingalpha.com/symbol/JNJ 


 http://www.mdmooc.org/ 

"MDMOOC" platform

Siemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash

Sarepta Therapeutics and University of Florida Announce Collaboration

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

image862

 DealsSiemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash


 BUSINESS NEWSAUGUST 2, 2020 / 4:04 AM / UPDATED AN HOUR AGO

Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian

Jörn Poltz, Douglas Busvine

4 MIN READ

MUNICH/BERLIN (Reuters)

 https://www.reuters.com/article/us-varian-med-syst-m-a-siemens-health-st/siemens-healthineers-to-acquire-varian-for-164-billion-idUSKBN24Y08W 



Siemens Healthineers to Buy Varian Medical for $16.4 Billion

Deal will create a leader in the area of cancer therapy

By Tom FairlessUpdated Aug. 2, 2020 8:37 am ET 

 https://www.wsj.com/articles/siemens-healthineers-to-buy-varian-medical-for-16-4-billion-11596371354 


 https://www.varian.com/ 


 https://seekingalpha.com/symbol/VAR 


 https://www.siemens-healthineers.com/en-us/ 


 

Siemens Healthineers Said to Near $15 Billion Purchase of Varian

Ed Hammond and Nabila Ahmed, Bloomberg News

 https://www.bnnbloomberg.ca/siemens-healthineers-said-to-near-15-billion-purchase-of-varian-1.1474159 

 

Siemens Healthineers near $15B deal for Varian - Bloomberg

Aug. 1, 2020 9:24 PM ET|About: Siemens Healthineers AG (SEMHF)|By: Carl Surran, SA News Editor  

 https://seekingalpha.com/news/3598683-siemens-healthineers-near-15b-deal-for-varian-bloomberg 


 https://seekingalpha.com/symbol/SEMHF 


Intelligent Cancer Care™ Everyone fighting cancer shares the same goal—beating it. Together, we can lead a more intelligent fight and realize our vision of a world without fear of cancer.

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

image863

 

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma

Fri July 31, 2020 2:00 AM|GlobeNewswire|About: BNTX

  • BioNTech (NTGN) and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade
  • Combines two immunotherapies with complementary mechanisms of action with the aim to accelerate the path to market approval in melanoma if the trial is successful
  • Development costs for the clinical trial to be shared equally with each company retaining full commercial rights to their respective product candidates

MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron


 https://biontech.de/ 


 For more information, please visit www.bioNTech.de 


 https://seekingalpha.com/symbol/BNTX 


 https://seekingalpha.com/symbol/REGN 


 https://www.libtayo.com/ 


 clinical trial evaluating the combination of PD-1 inhibitor Libtayo (cemiplimab) and the latter's BNT111 FixVac candidate for the second-line treatment of patients with advanced cutaneous melanoma 

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma

Sangamo teams up with Novartis in neurodevelopmental disorders

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

Sangamo teams up with Novartis in neurodevelopmental disorders

image864

 

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Thu July 30, 2020 7:00 AM|Business Wire|About: SGMO

- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (SGMO)


 www.sangamo.com. 


 https://www.businesswire.com/news/home/20200730005166/en/ 


 https://www.sangamo.com/pipeline 


 https://seekingalpha.com/symbol/SGMO 


 https://seekingalpha.com/symbol/NVS 


 https://seekingalpha.com/news/3597652-sangamo-teams-up-novartis-in-neurodevelopmental-disorders 


 

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

July 30, 2020 at 7:00 AM EDTDownload PDF

- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales

BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 30, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO)

 https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-global-collaboration-novartis-develop-genomic 



THERAPEUTIC PROGRAMS UNDER DEVELOPMENT

Elunate® (fruquintinib capsules)

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

Sangamo teams up with Novartis in neurodevelopmental disorders

image865

 

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Tue July 28, 2020 2:00 AM|GlobeNewswire|About: HCM

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company


 https://www.chi-med.com/ 


 in June 2018 (clinicaltrials.gov identifier: NCT02314819). 


  (clinicaltrials.gov identifier: NCT03251378). 


  (clinicaltrials.gov identifier: NCT04322539). 


  please visit: www.chi-med.com. 


  www.lilly.com. 


 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701622/ 

 

Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC

 https://clinicaltrials.gov/ct2/show/NCT04005066 



 https://seekingalpha.com/symbol/HCM 


 https://seekingalpha.com/symbol/LLY 

| 28 Jul 2020 Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly. The 2020 Amendment covers the expansion of Chi-Med’s role in the commercialization of Elunate® (fruquintinib capsules) in China.

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

image866

 

Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd

Published: Jul 27, 2020

BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, as well as various health and well-being-focused plant-based products


 about Shineco, please visit http://tianyiluobuma.com. 


 http://tianyiluobuma.com/ 


 For more information, please visit http://www.czbiowin.com/. 


 http://www.czbiowin.com/ 


 https://seekingalpha.com/symbol/TYHT 


 http://www.tianyiluobuma.com/index.php/English/Jishu/index.html 


 http://www.czbiowin.com/ 


Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd Mon July 27, 2020 9:00 AM|GlobeNewswire|About: TYHT BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. (TYHT)

Astrazeneca inks $6B oncology deal with Daiichi Sankyo

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

image867

 

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Mon July 27, 2020 2:00 AM|Business Wire|About: AZN, DSNKY

  • Agreement represents second collaboration between Daiichi Sankyo (DSKYY) and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC)
  • AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of future regulatory and sales milestones

TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (DSKYF) (hereafter, Daiichi Sankyo)


 https://www.businesswire.com/news/home/20200726005033/en/ 


 For more information, please visit: www.DSCancerEnterprise.com. 


 please visit: www.daiichisankyo.com. 


 

Astrazeneca inks $6B oncology deal with Daiichi Sankyo

Jul. 27, 2020 3:02 AM ET|About: AstraZeneca PLC (AZN)|By: Mamta Mayani, SA News Editor  

 https://seekingalpha.com/news/3595052-astrazeneca-inks-6b-oncology-deal-daiichi-sankyo 


 https://seekingalpha.com/symbol/DSKYF 


 https://seekingalpha.com/symbol/AZN 


 https://www.astrazeneca.com/ 

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate PUBLISHED 27 July 2020

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

image868

 

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

Thu July 23, 2020 7:00 AM|GlobeNewswire|About: OVID

  • Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome
  • Ovid and UConn to collaborate on genetic therapy for potential future use alone or in combination with OV101, Ovid’s small molecule therapy for Angelman syndrome in Phase 3 development

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.  (OVID)(NASDAQ: OVID)


 https://ovidrx.com/ 


 https://health.uconn.edu/ 


 https://seekingalpha.com/symbol/OVID 


 https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-and-university-connecticut-enter-strategic 



Our unique understanding of the complexities of neurologic systems allows us to turn clinical potential into clinical meaning. The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with certain rare neurological conditions, and all address significant markets.

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

image869

 

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Wed July 22, 2020 2:00 AM|GlobeNewswire|About: BVNRY

COPENHAGEN, Denmark, July 22, 2020 – Bavarian Nordic A/S (BVNKF)


 For more information visit: www.AdaptVac.com. 


 For more information visit www.bavarian-nordic.com. 


 https://www.bavarian-nordic.com/ 


 https://seekingalpha.com/symbol/BVNRY 


 https://www.adaptvac.com/pipeline 



BAVARIAN NORDIC AND ADAPTVAC SIGN FINAL LICENSE AGREEMENT ON COVID-19 VACCINE COPENHAGEN, Denmark, July 22, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of an agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of Copenhagen, to license AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses, including the COVID-19 indication.

Gilead secures stake in cancer immunotherapy developer Tizona

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Gilead secures stake in cancer immunotherapy developer Tizona

image870

 

Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

Tue July 21, 2020 8:30 AM|Business Wire|About: GILD

– Gilead to Acquire 49.9% Equity Interest in Tizona –

– Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments –

– Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc.


 https://www.businesswire.com/news/home/20200721005336/en/ 


 https://www.gilead.com/ 


 https://seekingalpha.com/symbol/GILD 


 https://www.tizonatx.com/ 


 

Gilead secures stake in cancer immunotherapy developer Tizona

Jul. 21, 2020 8:42 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor  

 https://seekingalpha.com/news/3593056-gilead-secures-stake-in-cancer-immunotherapy-developer-tizona 


 Tizona Therapeutics. 


Pipeline Overview Our oncology pipeline is focused on restoring and bolstering immune responses and includes TTX-030. For information about the TTX-030 Phase I/Ib trial, visit: www.clinicaltrials.gov.

Novocure teams up with Merck in lung cancer study

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Gilead secures stake in cancer immunotherapy developer Tizona

image871

 

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

Wed July 15, 2020 7:30 AM|Business Wire|About: NVCR

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.)


 https://www.novocure.com/ 


 https://seekingalpha.com/symbol/NVCR 


 https://www.businesswire.com/news/home/20200715005430/en/ 


 https://www.novocure.com/our-pipeline/ 


 https://seekingalpha.com/symbol/MRK 


 https://www.merck.com/index.html 


 https://www.novocure.com/novocure-announces-clinical-trial-collaboration-with-msd-to-evaluate-tumor-treating-fields-together-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer/ 



The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Tumor Treating Fields has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 19 years.

BiotechVortex™

Medtronic to Acquire Medicrea

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

image872

 

Medtronic to Acquire Medicrea

Wed July 15, 2020 2:30 AM|Business Wire|About: MDT, MRNTF, MRNTY

Medtronic will become the first company to offer an integrated solution including artificial intelligence-driven surgical planning, personalized spinal implants and robotic assisted surgery

DUBLIN & LYON, France--(BUSINESS WIRE)-- Medtronic plc (MDT), a global leader in medical technology, and Medicrea (MRNTF) (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF)


 https://seekingalpha.com/symbol/MRNTY 


 https://seekingalpha.com/symbol/MRNTF 


 Medicrea’s product portfolio includes MEDICREA® UNiD® ASI (Adaptive Spine Intelligence) designed to support surgeon workflow in pre-operative planning and create personalized implant solutions for surgery. 


  https://www.medtronic.com/uk-en/index.html 


 https://seekingalpha.com/symbol/MDT 


 https://www.medicrea.com/usa/ 


  https://www.businesswire.com/news/home/20200714006115/en/ 


 https://seekingalpha.com/symbol/MDT 






PASS® range The PASS® range by MEDICREA is a highly versatile, low-profile PolyAxial Spine System. Its unique concept allows connection to the rod from a distance, which minimizes stress and provides a strong platform for correction and fusion in all designated indications.

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

image873

  

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

Tue July 14, 2020 8:00 AM|Business Wire|About: IQV

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.


 https://www.iqvia.com/ 


 https://www.businesswire.com/news/home/20200714005159/en/ 


 https://seekingalpha.com/symbol/IQV 


 https://seekingalpha.com/symbol/AZN 



A time for action: fighting COVID-19 Last updated July 10, 2020

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

image874

 

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

Tue July 14, 2020 7:00 AM|PR Newswire|About: SNYPR Newswire

CAMBRIDGE, Mass. and HOUSTON, July 14, 2020 /PRNewswire/ -- Sanofi and The University of Texas MD Anderson Cancer Center 


 https://www.mdanderson.org/ 


 https://www.prnewswire.com/news-releases/sanofi-and-md-anderson-announce-strategic-collaboration-to-accelerate-oncology-research-and-development-301092433.html 


 https://seekingalpha.com/symbol/SNY 


 https://www.sanofi.com/ 







MD Anderson and Sanofi announce strategic collaboration to accelerate oncology research and development New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines MD Anderson News Release July 14, 2020 The University of Texas MD Anderson Cancer Center and Sanofi

Amgen Announces Additional Investment In BeiGene

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

image875

 

Amgen Announces Additional Investment In BeiGene

Sun July 12, 2020 10:01 PM|PR Newswire|About: AMGN

THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (AMGN)


 https://www.amgen.com/ 


 https://www.prnewswire.com/news-releases/amgen-announces-additional-investment-in-beigene-301091975.html 


 https://www.beigene.com/ 


 https://www.beigene.com/science-and-product-portfolio/pipeline 


 https://seekingalpha.com/symbol/AMGN 


 https://seekingalpha.com/symbol/BGNE 



Amgen Announces Additional Investment In BeiGene THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

image876

 

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

Thu June 11, 2020 9:00 AM|Business Wire|About: SVA

BEIJING & SAO PAULO--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (SVA), (“Sinovac” or the “Company”) (NASDAQ: SVA)


http://www.butantan.gov.br/ 


http://www.sinovac.com/ 


https://www.businesswire.com/news/home/20200611005491/en/ 


https://seekingalpha.com/symbol/SVA 


https://seekingalpha.com/news/3582301-sinovac-inks-deal-to-advance-covidminus-19-vaccine 


Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III Date: 2020-06-11 Pageview: 9803 BEIJING & SAO PAULO--Sinovac Biotech Ltd., (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, and Instituto Butantan,

Lilly teams up with Evox Therapeutics in neurological disorders

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

image877

 

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Tue June 9, 2020 7:00 AM|PR NewswirePR Newswire

OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEX™ platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders


 https://www.prnewswire.com/news-releases/evox-therapeutics-announces-a-multi-target-rnai-and-antisense-research-collaboration-and-license-agreement-with-lilly-301072380.html 


 

Lilly teams up with Evox Therapeutics in neurological disorders

Jun. 9, 2020 8:36 AM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3581471-lilly-teams-up-evox-therapeutics-in-neurological-disorders 


 https://www.evoxtherapeutics.com/ 


 https://www.evoxtherapeutics.com/Pipeline 


PIPELINE Utilising the DeliverEXTM platform, Evox is developing a proprietary pipeline of exosome-based therapeutics for treating life-threatening rare diseases. These therapeutics will have a transformative impact on the lives of patients suffering from rare diseases where there are currently few, if any, treatment options.

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

image878

 

Bristol Myers teams up with UbiVac in study of triplet therapy for breast cancer

Jun. 9, 2020 12:08 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor 


 

UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer. 

 https://www.ubivac.com/ 


 https://www.ubivac.com/technologies 


 https://seekingalpha.com/symbol/BMY 


 https://www.ubivac.com/press-releases/2020/6/9/ubivac-announces-clinical-trial-collaboration-with-bristol-myers-squibb-on-combination-immunotherapy-for-advanced-triple-negative-breast-cancer 



Technologies

AbbVie and Genmab Announce Broad Oncology Collaboration

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

image879

 

AbbVie and Genmab Announce Broad Oncology Collaboration

Wed June 10, 2020 6:00 AM|PR Newswire|About: ABBV, GMAB

- Companies establish a discovery research collaboration to create additional differentiated antibody therapeutics for cancer

- AbbVie to pay Genmab an upfront payment of USD 750 million with total potential milestone payments of up to USD 3.15 billion

PR Newswire

NORTH CHICAGO, Illinois and COPENHAGEN, Denmark, June 10, 2020 /PRNewswire/ -- AbbVie (ABBV) and Genmab A/S (GNMSF) (Nasdaq: GMAB)


 https://www.genmab.com/ 


 https://seekingalpha.com/symbol/GMAB 


 https://www.genmab.com/product-pipeline 


 https://www.abbvie.com/ 


 https://news.abbvie.com/news/press-releases/abbvie-and-genmab-announce-broad-oncology-collaboration.htm 


 https://www.prnewswire.com/news-releases/abbvie-and-genmab-announce-broad-oncology-collaboration-301073533.html 



 Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA™ is a trademark of Horizon Therapeutics plc. 


 https://seekingalpha.com/symbol/ABBV 




Product pipeline Genmab has three approved products in collaboration, DARZALEX® (daratumumab), Arzerra® (ofatumumab) and TEPEZZA™ (teprotumumab-trbw), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.

Sequencing by Expansion (SBX™)

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

image880

 

Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use

  • Genomics insights generated through sequencing an individual's DNA play a critical role in personalised healthcare and clinical diagnostics of the future
  • Roche is committed to developing a nanopore sequencer with the aim of providing the healthcare community and ultimately patients with faster and more accurate medical information to predict risk and detect disease
  • This investment complements the development of Roche’s nanopore technology with the goal of an end-to-end sequencing solution starting from a patient sample to a diagnostic result

Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY)


 

Roche acquires nanopore sequencing developer Stratos Genomics

May 22, 2020 8:17 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3577123-roche-acquires-nanopore-sequencing-developer-stratos-genomics 


 https://www.stratosgenomics.com/ 


 https://seekingalpha.com/symbol/RHHBY 

Sequencing by Expansion (SBX™) Stratos Genomics is Delivering on the Promise of Nanopore Sequencing

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

image881

 

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Mon May 11, 2020 7:00 AM|PR Newswire|About: REGN 

 TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ --

Regeneron Genetics Center will sequence 450,000 informed and consented patients


 https://www.cuanschutz.edu/ 


 https://www.regeneron.com/ 


 https://www.prnewswire.com/news-releases/regeneron-and-colorado-center-for-personalized-medicine-announce-major-new-human-genetics-research-collaboration-301056116.html 


 https://www.cu.edu/ 


 https://medschool.cuanschutz.edu/ccpm 


 https://seekingalpha.com/symbol/REGN 




May 11, 2020 at 7:00 AM EDT Back REGENERON AND COLORADO CENTER FOR PERSONALIZED MEDICINE ANNOUNCE MAJOR NEW HUMAN GENETICS RESEARCH COLLABORATION TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health records to aid in genomic medicine, drug discovery and personalized medicine approaches Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM)

novel HSV-2 vaccine

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

image882

 

Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens

Tue May 19, 2020 7:30 AM|GlobeNewswire|About: GNCA

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA) (NASDAQ: GNCA)


 https://www.genocea.com/ 


 http://www.shionogi.co.jp/en/ 


 https://www.shionogi.com/us/en/ 


 https://seekingalpha.com/symbol/SGIOY 


 https://seekingalpha.com/symbol/GNCA 



GENOCEA ANNOUNCES MATERIAL TRANSFER AND LICENSE OPTION AGREEMENT WITH SHIONOGI FOR PROPRIETARY GEN-003 HSV-2 ANTIGENS May 19, 2020 at 7:30 AM EDT CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017.

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

image883

 

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Tue May 19, 2020 3:05 AM|PR Newswire|About: RHHBY

Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments

PR Newswire

SAN DIEGO, May 19, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology 


 https://vividion.com/ 


 https://www.prnewswire.com/news-releases/vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases-301061339.html 


 https://seekingalpha.com/symbol/RHHBY 


 https://vividion.com/wp-content/uploads/2020/05/Roche-Vividion-Press-Release_vFINAL.pdf 

The Small Molecule Company of the Future

BiotechVortex™

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

image884

 

Roche teams up with Arrakis Therapeutics in RNA-targeted small molecules

Apr. 8, 2020 12:01 PM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor  


 https://www.businesswire.com/news/home/20200408005184/en/Arrakis-Therapeutics-Enters-Strategic-Collaboration-License-Agreement 


 https://arrakistx.com/ 


 https://seekingalpha.com/symbol/RHHBY 


 https://arrakistx.com/pipeline/ 


 https://arrakistx.com/news/press-releases/arrakis-therapeutics-enters-strategic-collaboration-and-license-agreement-with-roche/ 



Our Pipeline of rSM Medicines We have taken a multi-pronged approach to building our pipeline of RNA-targeted small molecule (rSM) medicines by pursuing deeply researched, valuable protein drug targets, including:

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

image885

 

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

Thu April 9, 2020 7:50 AM|Business Wire|About: BNTX, PFE

  • Pfizer (PFE) and BioNTech (BNTX) to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
  • Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021.
  • BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
  • Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
  • BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million

MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE, and Pfizer Inc. 


 

https://www.businesswire.com/news/home/20200409005405/en/ 

https://www.pfizer.com/ 

https://seekingalpha.com/news/3559589-pfizer-identifies-lead-covidminus-19-candidate 

https://biontech.de/ 

https://seekingalpha.com/symbol/BNTX 

https://seekingalpha.com/symbol/PFE 

Pfizer Identifies Lead Coronavirus Drug Candidate

Experimental medicine to be tested on patients this summer; arthritis therapy Xeljanz considered, too

By Jared S. Hopkins

JAREDSHOPKINS

Updated April 9, 2020 3:56 pm ET 

https://www.wsj.com/articles/pfizer-identifies-lead-coronavirus-drug-candidate-11586427303?mod=pls_whats_news_us_business_f